WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales SHANGHAI, Jan. 5, 2023 /PRNewswire/ -- WuXi...
DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference...
Innovent Announces NMPA’s Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for...
Cognos Therapeutics, Inc. to Become Publicly Listed on Nasdaq via Business Combination with Nocturne Acquisition Corporation
Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. Cognos' lead product candidate is the SINNAISTM Implantable Smart Pump, believed to be the world's first implantable device under development for...
CGTN: China’s preparedness for adjusting its COVID-19 policies
BEIJING, Jan. 5, 2023 /PRNewswire/ -- Since China prioritized its COVID-19 response from the dynamic zero-COVID policy, some Western media and intellectuals have been questioning China's "preparedness" of making the change. Preparedness can only be evaluated by the results to which it leads – in the case of COVID-19, the number of lives...
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference held on...
NuraLogix Announces ‘Holy Grail’ of Blood Pressure Measurement
LAS VEGAS, Jan. 4, 2023 /PRNewswire/ -- Researchers at NuraLogix, a global leader in Health Tech AI, announced today that they have achieved the 'Holy Grail' of contactless blood pressure (BP) measurement using the company's TOI™ based Anura™ app! NuraLogix Announces ‘Holy Grail’ of Blood Pressure Measurement "What is the Holy Grail of contactless blood pressure measurement? It's...
IMG Welcomes Scott Ackerman as Chief Commercial Officer
INDIANAPOLIS, Jan. 4, 2023 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning global insurance benefits and assistance services company, is pleased to introduce Scott Ackerman as the company's new Chief Commercial Officer. Scott joins the IMG team with 30 years of experience in the travel and insurance industries. "I couldn't be more excited...
Lunit to Supply AI Solution for Chest X-Ray Analysis to Albert Einstein, Latin America’s Largest Hospital
Lunit signed a software license agreement with the Hospital Israelita Albert Einstein, Latin America's top medical institution, to provide its AI-based chest x-ray solution Under the agreement, Lunit will supply its AI solution for chest x-ray image analysis to the Hospital Israelita Albert Einstein for three years until 2025. SEOUL,...
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise,...
